A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

Part A Healthy Volunteers

Part B and Part C (starts after treatment for Part A has completed) Participants with Obesity

Key Inclusion Criteria

Part A

• Male or female participants age ≥18 to ≤55 years of age at the time of screening
• BMI ≥18 and ≤32 kg/m2, at the screening visit

Part B and Part C

• Male or female participants ≥18 to ≤80 years of age at the time of screening
• BMI ≥30 kg/m2, at the screening visit
• History of 1 or more self-reported unsuccessful dietary attempts to lose weight

Key Exclusion Criteria

• History of diabetes (Type 2 or Type 1). History of gestational diabetes is permitted
• Previous bariatric surgery or planned bariatric surgery
• History of hypertrophic cardiomyopathy
• Abnormal electrocardiogram (ECG) findings at screening that meet Cornell voltage criteria for left ventricular hypertrophy
• Any malignancy in the past 5 years prior to screening (except for nonmelanoma skin cancer that has been resected with no evidence of metastatic disease for 3 years prior to screening)
• History of poorly controlled hypertension, as defined in the protocol
• Have a history of any other condition (such as known drug abuse, alcohol abuse, diagnosed eating disorder, or a severe mental illness) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol
• Have history of use of marijuana/tetrahydrocannabinol (THC) within 90 days prior to Visit 1 of enrollment and are unwilling to abstain from marijuana/THC use during the trial
• Has a history of any neuromuscular disorder (eg, multiple sclerosis, myasthenia gravis, myopathy, peripheral neuropathy, etc)

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply